Single-Chain Insulin Analog Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild-type insulin has a short half-life due to its two-chain configuration, which is readily reduced into inactive a- and b-chains in circulation, requiring frequent injections for glucose regulation in diabetic patients.
Innovation Solution
Development of single-chain polypeptide (SPC) insulin by covalently linking the a- and b-chains of insulin using an optimized amino-acid linker, preventing separation into inactive chains and extending the duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type insulin is used with two-chain configuration, then insulin can be produced and secreted by pancreatic beta cells, but the half-life in circulation is short (4-6 minutes) due to ready reduction into inactive chains
Solution Approach 1:
The patent merges the separate A-chain and B-chain of insulin into a single polypeptide chain by introducing a linker sequence. This combining prevents the disulfide bond reduction that separates the chains in wild-type insulin, thereby extending circulation half-life from 4-6 minutes to a significantly longer duration while maintaining biological activity.
2Reliability
If regular insulin requires multiple injections daily, then glucose regulation can be achieved, but patient convenience and compliance are reduced
Solution Approach 1:
By combining the insulin chains into a single polypeptide structure, the invention creates a formulation that maintains activity longer in circulation. This eliminates the need for multiple daily injections, improving patient convenience and compliance while sustaining effective glucose regulation throughout an extended period.
3Duration of action of moving object
If chemically synthesized single-chain insulin analogs are created, then duration of action is extended, but production complexity and side effects from chemical groups increase
Solution Approach 1:
The patent replaces complex chemical synthesis methods with a biological production system using recombinant DNA technology. The single-chain insulin is produced as a recombinant polypeptide in expression systems, eliminating the need for chemical synthesis steps, added chemical groups, and associated purification complexities while achieving extended duration of action.
4Productivity
If proinsulin is used for production, then biosynthesis yield can be increased, but contamination from inactive proinsulin remains an issue
Solution Approach 1:
The invention extracts and eliminates the problematic C-peptide portion of proinsulin while retaining the functional A and B chains. By designing a recombinant single-chain insulin that directly encodes only the necessary chains connected by a linker, the method produces active insulin without generating inactive proinsulin contamination, achieving both high yield and high purity.
Data Source
AI summary
Described herein are single chain polypeptides comprising both the b- and a-chains of insulin fused to each other by a linker. Also provided are nucleic acids coding for the same, host cells expressing the same, and methods of use therefor.